Product logins

Find logins to all Clarivate products below.


Biosimilars | Access & Reimbursement | Global | 2016

The regulatory and market access environment for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, staying ahead of the similarities and differences between each country can be a major challenge. The Access & Reimbursement Overview allows rapid assessment of key parameters including the scope of biosimilars guidelines, choice of reference product, pricing mechanisms for biosimilars, and strategies in place to drive uptake across the United States, EU5, Japan, Australia, Canada, and the leading growth markets.

Related Market Assessment Reports

Report
Biosimilars – Forecast – Neurology
In 2024, sales of branded MAb biologics in neurology exceeded $12 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2024-2034 forecast period, the…
Report
Biosimilars – Forecast – Ophthalmology
In 2024, sales of branded biologics in ophthalmology exceeded $6.7 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2024-2034 forecast period…
Report
Biosimilars – Forecast – Respiratory
In 2024, sales of branded biologics for respiratory indications totaled $7 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout the 2024-2034 forecast…
Report
Biosimilars – Forecast – Endocrinology
In 2024, sales of branded biologics for endocrinology indications (insulins and antiresorptive analogues) exceeded $22 billion in the major pharmaceutical markets under study (United States, EU5,…
Report
Biosimilars – Forecast – Immunology
In 2024, sales of branded biologics in immunology exceeded $65 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Sales of biosimilars in the major market in…